Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9103813 | 1.00 | MET (1.00) | MET | |
| SCHEMBL9103797 | 1.00 | MET (1.00) | MET | |
| SCHEMBL29435059 | 1.00 | MET (1.00) | MET | |
| SCHEMBL9102946 | 0.93 | MET (1.00) | MET | |
| SCHEMBL9102938 | 0.93 | MET (1.00) | MET | |
| SCHEMBL9100431 | 0.92 | MET (0.85) | MET | |
| SCHEMBL9101726 | 0.92 | MET (0.85) | MET | |
| SCHEMBL9103335 | 0.92 | MET (1.00) | MET | |
| SCHEMBL9103321 | 0.92 | MET (1.00) | MET | |
| SCHEMBL9103331 | 0.92 | MET (1.00) | MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180098995-A1 | Combination Products with Tyrosine Kinase Inhibitors and their Use | NOVARTIS AG (CH) | 2018-04-12 | — | — | US | claimed |
| US-20150297604-A1 | Combination Products with Tyrosine Kinase Inhibitors and their Use | NOVARTIS AG (CH) | 2015-10-22 | — | — | US | claimed |
| US-20150051210-A1 | Tyrosine Kinase Inhibitor Combinations and their Use | NOVARTIS AG (CH) | 2015-02-19 | — | — | US | claimed |
| EP-2833917-A1 | TYROSINE KINASE INHIBITOR COMBINATIONS AND THEIR USE | Novartis AG (CH) | 2015-02-11 | — | — | EP | claimed |
| EP-2834246-A1 | COMBINATION PRODUCTS WITH TYROSINE KINASE INHIBITORS AND THEIR USE | Novartis AG (CH) | 2015-02-11 | — | — | EP | claimed |
| WO-2014174478-A1 | PHARMACEUTICAL COMBINATIONS OF A PKC INHIBITOR AND A C-MET RECEPTOR TYROSINE KINASE INHIBITOR | NOVARTIS AG (CH) | 2014-10-30 | — | — | WO | claimed |
| WO-2013151913-A1 | TYROSINE KINASE INHIBITOR COMBINATIONS AND THEIR USE | NOVARTIS AG (CH) | 2013-10-10 | — | — | WO | claimed |
| WO-2013149581-A1 | COMBINATION PRODUCTS WITH TYROSINE KINASE INHIBITORS AND THEIR USE | NOVARTIS AG (CH) | 2013-10-10 | — | — | WO | claimed |
| US-8497368-B2 | Heterocyclic hydrazone compounds | NOVARTIS AG (CH) | 2013-07-30 | — | — | US | claimed |
| US-12351571-B2 | Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases | ARRAY BIOPHARMA INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-11918576-B2 | Combination of an FGFR inhibitor and a CMET inhibitor | ASTEX THERAPEUTICS LTD (GB) | 2024-03-05 | — | — | US | disclosed |
| US-20220081438-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | ARRAY BIOPHARMA INC. | 2022-03-17 | — | — | US | disclosed |
| EP-3964513-A1 | COMBINATION PRODUCTS WITH TYROSINE KINASE INHIBITORS AND THEIR USE | Novartis AG (CH) | 2022-03-09 | — | — | EP | disclosed |
| EP-3898615-A1 | 7-((3,5-DIMETHOXYPHENYL)AMINO)QUINOXALINE DERIVATIVES AS FGFR INHIBITORS FOR TREATING CANCER | Array Biopharma, Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-2833917-A1 | TYROSINE KINASE INHIBITOR COMBINATIONS AND THEIR USE | Novartis AG (CH) | 2015-02-11 | — | — | EP | disclosed |
| WO-2014174478-A1 | PHARMACEUTICAL COMBINATIONS OF A PKC INHIBITOR AND A C-MET RECEPTOR TYROSINE KINASE INHIBITOR | NOVARTIS AG (CH) | 2014-10-30 | — | — | WO | disclosed |
| WO-2013151913-A1 | TYROSINE KINASE INHIBITOR COMBINATIONS AND THEIR USE | NOVARTIS AG (CH) | 2013-10-10 | — | — | WO | disclosed |
| WO-2013149581-A1 | COMBINATION PRODUCTS WITH TYROSINE KINASE INHIBITORS AND THEIR USE | NOVARTIS AG (CH) | 2013-10-10 | — | — | WO | disclosed |
| US-8497368-B2 | Heterocyclic hydrazone compounds | NOVARTIS AG (CH) | 2013-07-30 | — | — | US | disclosed |
| US-20120142681-A1 | HETEROCYCLIC HYDRAZONE COMPOUNDS | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180098995-A1 | Combination Products with Tyrosine Kinase Inhibitors and their Use | EGFR, ERBB2, ERBB3 | MET 4/4885 |
| US-11918576-B2 | Combination of an FGFR inhibitor and a CMET inhibitor | FGFR3, FGFR1, FGFR2 | MET 5/4885 |
| US-20120142681-A1 | HETEROCYCLIC HYDRAZONE COMPOUNDS | MET, HGF, RET | MET 1/4885 |
| US-20150051210-A1 | Tyrosine Kinase Inhibitor Combinations and their Use | MET, FGFR3, FGFR1 | MET 1/4885 |
| US-20150297604-A1 | Combination Products with Tyrosine Kinase Inhibitors and their Use | EGFR, ERBB2, ERBB3 | MET 4/4885 |
| US-20220081438-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | FGFR1, FGFR4, FGFR3 | MET 184/4885 |
| US-12351571-B2 | Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases | FGFR3, FGFR4, FGFR1 | MET 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.